Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New eye drop could make retina injections less painful

NCT ID NCT05747430

First seen Apr 14, 2026 · Last updated Jun 23, 2026 · Updated 11 times

Summary

This study tested a new antiseptic called IRX-101 against the standard povidone-iodine in 155 people receiving eye injections for retinal disease. The goal was to see if IRX-101 causes less pain and less damage to the cornea. Researchers measured safety and corneal staining to compare the two treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINAL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Charleston Neuroscience Institute

    Ladson, South Carolina, 29456, United States

  • Coastal Eye Surgeons, LLC

    Greenwich, Connecticut, 06830, United States

  • Edward Wood, MD

    Round Rock, Texas, 78681, United States

  • Erie Retina Research, LLC

    Erie, Pennsylvania, 16507, United States

  • Mississippi Retina Associates

    Madison, Mississippi, 39110, United States

  • Retina Associates of Utah

    Salt Lake City, Utah, 84107, United States

  • Retina Consultants of Texas

    Katy, Texas, 77494, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

IRX-101 (a novel eye antiseptic)

What this could lead to

If it works, IRX-101 could make eye injections less painful and reduce damage to the cornea, improving comfort for people with retinal disease.

What could go wrong

This is a small, early-phase trial (155 people) testing a new drug. It may not prove better than the standard antiseptic, and safety is still being checked.

Conditions

The condition(s) this trial relates to.

retinal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.